Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Frequently asked questions
What sector does Kuros Biosciences AG (KURN) operate in?
Kuros Biosciences AG belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Kuros Biosciences AG (KURN) current stock price?
As of the latest data, Kuros Biosciences AG stock price is CHF 23.14, with a previous close of CHF 23.00. Kuros Biosciences AG gained CHF 0.14 in the last trading session, representing a 0.61% increase.
What is Kuros Biosciences AG (KURN) current market capitalization?
Kuros Biosciences AG market cap is approximately 912.63 million.
What is Kuros Biosciences AG (KURN) Earnings Per Share (EPS)?
The trailing EPS is CHF 0.06, and the forward EPS is CHF 0.51.
What is Kuros Biosciences AG (KURN) Price-to-Earnings (P/E) ratio?
Kuros Biosciences AG current P/E ratio is 385.67, with a forward P/E of 45.55.
Does Kuros Biosciences AG (KURN) pay dividends?
No. Kuros Biosciences AG does not pay a dividend.
When is Kuros Biosciences AG (KURN) next earnings report?
Kuros Biosciences AG is expected to release its next earnings report on June 30, 2026.
What is Kuros Biosciences AG (KURN) beta (volatility) score?
Kuros Biosciences AG has a beta of 0.761, indicating lower volatility than the overall market.
